Abstract
To analyze the expression of the transforming acidic coiled-coil protein 3 (TACC3) in esophageal squamous cell carcinoma (ESCC) samples, and to identify whether TACC3 can serve as a biomarker for the diagnosis and prognosis of ESCC, qPCR, western blotting and immunohistochemistry staining (IHC) were utilized to detect the expression of TACC3. Furthermore, cell growth, colony formation, migration ability and the epithelial-mesenchymal transition markers of ESCC cells in which TACC3 were knocked-down were measured. The mRNA and protein levels of TACC3 were higher in ESCC specimens compared to non-tumorous esophageal epithelial tissues. IHC results revealed TACC3 expression was significantly correlated to differentiation (p = 0.017) and lymphoid nodal status (p = 0.028). The patients with high-expression of TACC3 had a significantly poor prognosis compared to those of low-expression (p = 0.017), especially in the patients at stages I-II (p = 0.028). Multivariate analysis indicated that TACC3 expression was an independent prognostic factor for ESCC patients (p = 0.025). Knockdown of TACC3 inhibited the ability of cell proliferation, colony formation and migration. This study first identifies TACC3 not only as a useful biomarker for diagnose and prognosis of ESCC, but also as a potential therapeutic target for patients with ESCC.
Highlights
Esophageal cancer, the eighth most common cancer in the world, is composed of two main histologic types: squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) [1]
We performed quantitative reverse transcriptase PCR (qRT-PCR) and western blotting in 28 pairs of matched esophageal squamous cell carcinoma (ESCC) tissue and adjacent noncancerous tissue to examine whether the high expression of transforming acidic coiled-coil protein 3 (TACC3) occurred in ESCC patients
The expression level of TACC3 in ESCC tissues is significantly higher than the www.impactjournals.com/oncotarget level in matched normal tissues by quantitative analysis (Figure 1D)
Summary
Esophageal cancer, the eighth most common cancer in the world, is composed of two main histologic types: squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) [1]. More than 480,000 patients are diagnosed with esophageal cancer and 400,000 of the patients die of esophageal cancer, annually [2]. In North-Central China, referred to as the “esophageal cancer belt”, 90% of cases are squamous cell carcinomas [3]. Despite the efforts to improve the effectiveness of the combination of surgical approach and radiochemotherapy, there is an immense clinical need for new therapeutic strategies and molecular targets. The clear cellular and molecular mechanisms leading to ESCC have not been systematically evaluated to date. A lack of efficient molecular predictors and exact mechanisms for esophageal cancer are the critical barriers for developing clinical useful strategies for esophageal cancer managements
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
